In this section, you will be presented with a description of the
ARV regimens you wish to evaluate including their efficacies and dose patterns.
The corresponding Excel spreadsheet is called ARVs.
The choice of ARVs, doses, timing of doses and estimated
efficacy of these regimens are derived from clinical trials and are given by the
model (blue cells). The trial-derived efficacy figures can then be adjusted to
reflect imperfect adherence (relevant if you believe that adherence in your
setting will be different from adherence in the trials); and late arrival for
treatment (relevant for the three regimens with a prepartum component - ACTG
076; CDC-Thai; and PETRA-A). In addition, the user enters the cost of each dose
to mother and to infant. Based on this cost data, the intended number of doses
in the regimen, and the number of mothers who receive each component of the
regimen, the model then calculates the drug costs per woman and annual drug
costs for the expected number of women to be treated in the service